428 is the total number of securities DAFNA Capital Management LLC has owned. The longest DAFNA Capital Management LLC has owned a single stock is 42 quarters.
Period | Weighting | Quarter | |||||||
---|---|---|---|---|---|---|---|---|---|
Ticker | Name | Longest | Shortest | Min. | Avg. | Max. | First | Latest | ↓ Count |
STXS | STEREOTAXIS INC | 42 | 42 | 0.50% | 8.33% | 27.58% | Q2 2013 | Q3 2023 | 42 |
ATRC | ATRICURE INC | 42 | 42 | 0.76% | 4.94% | 11.43% | Q2 2013 | Q3 2023 | 42 |
MASI | MASIMO CORPORATION | 42 | 42 | 0.08% | 0.45% | 1.76% | Q2 2013 | Q3 2023 | 42 |
ASND | ASCENDIS PHARMA A S SP... | 26 | 8 | 0.20% | 1.79% | 4.48% | Q1 2015 | Q3 2023 | 34 |
AERI | AERIE PHARMACEUTICALS INC | 33 | 33 | 0.51% | 2.29% | 4.17% | Q3 2014 | Q3 2022 | 33 |
GLPG | GALAPAGOS NV-SPON ADR | 33 | 33 | 0.07% | 1.83% | 3.79% | Q3 2015 | Q3 2023 | 33 |
XENE | XENON PHARMACEUTICALS INC | 33 | 33 | 0.20% | 1.78% | 3.64% | Q3 2015 | Q3 2023 | 33 |
NBIX | NEUROCRINE BIOSCIENCES... | 31 | 1 | 1.04% | 2.18% | 2.90% | Q3 2014 | Q3 2023 | 32 |
JNJ | JOHNSON AND JOHNSON | 32 | 32 | 0.37% | 0.72% | 1.18% | Q2 2013 | Q1 2021 | 32 |
IBB | ISHARES TR NASDQ BIOTECH | 28 | 2 | 1.22% | 2.37% | 3.97% | Q1 2016 | Q3 2023 | 30 |
BEAT | BIOTELEMETRY INC | 30 | 30 | 0.11% | 1.46% | 3.34% | Q3 2013 | Q4 2020 | 30 |
BPMC | BLUEPRINT MEDICINES CORP | 28 | 1 | 0.16% | 3.94% | 7.02% | Q2 2016 | Q3 2023 | 29 |
RIGL | RIGEL PHARMACEUTICALS INC | 14 | 6 | 0.08% | 1.11% | 3.37% | Q4 2014 | Q2 2022 | 28 |
BCRX | BIOCRYST PHARMACEUTICA... | 16 | 4 | 0.36% | 1.62% | 3.88% | Q3 2014 | Q3 2023 | 27 |
MGNX | MACROGENICS INC | 19 | 1 | 0.08% | 0.78% | 1.88% | Q3 2015 | Q3 2023 | 26 |
DXCM | DEXCOM INC | 25 | 25 | 1.47% | 2.28% | 3.75% | Q3 2017 | Q3 2023 | 25 |
AGTC | APPLIED GENETIC TECHNO... | 25 | 25 | 0.44% | 1.38% | 2.86% | Q1 2015 | Q1 2021 | 25 |
KURA | KURA ONCOLOGY INC | 25 | 25 | 0.09% | 0.80% | 2.04% | Q3 2017 | Q3 2023 | 25 |
BLUE | BLUEBIRD BIO INC | 14 | 11 | 0.19% | 0.69% | 1.83% | Q3 2014 | Q4 2020 | 25 |
RDUS | RADIUS HEALTH INC | 17 | 8 | 0.05% | 0.56% | 1.80% | Q1 2016 | Q2 2022 | 25 |
CARA | CARA THERAPEUTICS INC | 16 | 8 | 0.56% | 1.36% | 2.60% | Q2 2015 | Q2 2021 | 24 |
ACHN | ACHILLION PHARMACEUTICALS | 22 | 2 | 0.26% | 1.35% | 3.60% | Q2 2013 | Q4 2019 | 24 |
NXTM | NXSTAGE MEDICAL INC | 23 | 23 | 2.82% | 4.64% | 7.16% | Q2 2013 | Q4 2018 | 23 |
SAGE | SAGE THERAPEUTICS INC | 23 | 23 | 1.56% | 3.78% | 8.52% | Q4 2017 | Q2 2023 | 23 |
CYTK | CYTOKINETICS INC | 9 | 5 | 0.25% | 1.70% | 4.39% | Q4 2015 | Q3 2023 | 21 |
ZGNX | ZOGENIX INC | 21 | 21 | 0.40% | 1.54% | 3.08% | Q2 2015 | Q2 2020 | 21 |
PRQR | PROQR THERAPEUTICS NV | 17 | 1 | 0.13% | 1.26% | 3.79% | Q4 2017 | Q3 2023 | 21 |
SCYX | SCYNEXIS INC | 19 | 2 | 0.30% | 0.68% | 1.20% | Q2 2014 | Q4 2019 | 21 |
NTUS | NATUS MED INC | 21 | 21 | 0.16% | 0.56% | 1.30% | Q2 2017 | Q2 2022 | 21 |
PODD | INSULET CORP | 20 | 20 | 1.21% | 3.14% | 5.75% | Q2 2013 | Q1 2018 | 20 |
DRNA | DICERNA PHARMACEUTICAL... | 14 | 6 | 0.28% | 1.57% | 3.99% | Q2 2015 | Q3 2021 | 20 |
RADIUS HEALTH INC | 20 | 20 | 0.78% | 1.31% | 2.48% | Q3 2017 | Q2 2022 | 20 | |
CSII | CARDIOVASCULAR SYSTEMS... | 20 | 20 | 0.75% | 1.23% | 1.97% | Q2 2018 | Q1 2023 | 20 |
CBAY | CYMABAY THERAPEUTICS I... | 11 | 1 | 0.08% | 1.09% | 2.18% | Q1 2017 | Q4 2022 | 20 |
ARDX | ARDELYX INC | 19 | 1 | 0.21% | 0.92% | 2.37% | Q2 2014 | Q3 2020 | 20 |
AFMD | AFFIMED THERAPEUTICS BV | 13 | 1 | 0.14% | 0.78% | 1.86% | Q3 2014 | Q4 2022 | 20 |
VKTX | VIKING THERAPEUTICS INC | 20 | 20 | 0.35% | 0.78% | 1.59% | Q4 2018 | Q3 2023 | 20 |
KALV | KALVISTA PHARMACEUTICA... | 11 | 9 | 0.11% | 0.70% | 1.81% | Q3 2018 | Q3 2023 | 20 |
STRO | SUTRO BIOPHARMA INC | 17 | 3 | 0.12% | 0.24% | 0.55% | Q3 2018 | Q3 2023 | 20 |
FATE | FATE THERAPEUTICS INC | 15 | 4 | 0.08% | 3.57% | 9.05% | Q2 2014 | Q4 2022 | 19 |
EXAC | EXACTECH INC | 19 | 19 | 0.49% | 0.66% | 0.97% | Q2 2013 | Q4 2017 | 19 |
MRSN | MERSANA THERAPEUTICS INC | 19 | 19 | 0.21% | 0.59% | 1.82% | Q1 2019 | Q3 2023 | 19 |
INGN | INOGEN INC | 19 | 19 | 0.02% | 0.22% | 0.58% | Q1 2019 | Q3 2023 | 19 |
BHVN | BIOHAVEN PHARMACTL HLD... | 18 | 18 | 0.44% | 1.97% | 4.48% | Q2 2018 | Q3 2022 | 18 |
ALEC | ALECTOR INC | 9 | 9 | 0.16% | 0.92% | 1.56% | Q1 2019 | Q3 2023 | 18 |
ARAY | ACCURAY INC | 18 | 18 | 0.40% | 0.84% | 1.29% | Q2 2019 | Q3 2023 | 18 |
ALDR | ALDER BIOPHARMACEUTICA... | 17 | 17 | 0.53% | 2.73% | 4.51% | Q3 2015 | Q3 2019 | 17 |
ARNA | ARENA PHARMACEUTICALS INC | 16 | 1 | 0.19% | 2.01% | 4.45% | Q2 2017 | Q4 2021 | 17 |
KRTX | KARUNA THERAPEUTICS INC | 15 | 2 | 0.07% | 1.70% | 4.28% | Q2 2019 | Q3 2023 | 17 |
AKBA | AKEBIA THERAPEUTICS INC | 15 | 2 | 0.15% | 1.66% | 2.99% | Q1 2016 | Q3 2020 | 17 |
DERM | DERMIRA INC | 15 | 2 | 0.02% | 1.19% | 4.49% | Q2 2015 | Q3 2019 | 17 |
SPNC | SPECTRANETICS CORP | 17 | 17 | 0.78% | 1.16% | 1.61% | Q2 2013 | Q2 2017 | 17 |
ELOS | SYNERON MEDICAL LTD | 17 | 17 | 0.43% | 0.77% | 1.16% | Q2 2013 | Q2 2017 | 17 |
STIM | NEURONETICS INC | 17 | 17 | 0.13% | 0.49% | 1.47% | Q3 2019 | Q3 2023 | 17 |
PHAS | PHASEBIO PHARMACEUTICA... | 17 | 17 | 0.00% | 0.37% | 0.99% | Q4 2018 | Q4 2022 | 17 |
NXTC | NEXTCURE INC | 16 | 1 | 0.07% | 0.22% | 0.54% | Q2 2019 | Q3 2023 | 17 |
NVDQ | NOVADAQ TECHNOLOGIES INC | 16 | 16 | 0.63% | 2.71% | 9.09% | Q2 2013 | Q1 2017 | 16 |
MORF | MORPHIC HOLDING INC | 12 | 1 | 0.22% | 1.53% | 3.24% | Q2 2019 | Q3 2023 | 16 |
LMNX | LUMINEX CORP DEL | 16 | 16 | 0.26% | 1.44% | 2.35% | Q3 2017 | Q2 2021 | 16 |
FOMX | FOAMIX PHARMACEUTICALS... | 16 | 16 | 0.35% | 1.15% | 2.62% | Q4 2015 | Q3 2019 | 16 |
RCUS | ARCUS BIOSCIENCES INC | 15 | 1 | 0.06% | 0.81% | 1.30% | Q1 2018 | Q3 2023 | 16 |
LOXO | LOXO ONCOLOGY INC | 15 | 15 | 0.19% | 7.68% | 17.37% | Q2 2015 | Q4 2018 | 15 |
DSCI | DERMA SCIENCES INC | 15 | 15 | 0.64% | 1.97% | 4.22% | Q2 2013 | Q4 2016 | 15 |
PROTALIX BIOTHERAPEUTI... | 15 | 15 | 1.03% | 1.64% | 2.70% | Q4 2014 | Q2 2018 | 15 | |
OTIC | OTONOMY INC | 12 | 3 | 0.12% | 0.95% | 2.17% | Q1 2015 | Q3 2022 | 15 |
KDMN | KADMON HOLDINGS INC | 14 | 1 | 0.07% | 0.53% | 0.97% | Q3 2017 | Q3 2021 | 15 |
CGEN | COMPUGEN LTD | 15 | 15 | 0.04% | 0.40% | 1.82% | Q1 2020 | Q3 2023 | 15 |
MDGL | MADRIGAL PHARMACEUTICA... | 15 | 15 | 0.06% | 0.22% | 0.42% | Q4 2018 | Q2 2022 | 15 |
IMMU | IMMUNOMEDICS INC | 12 | 2 | 0.04% | 2.33% | 7.21% | Q2 2016 | Q3 2020 | 14 |
INSULET CORP | 14 | 14 | 1.73% | 2.10% | 2.70% | Q2 2014 | Q3 2017 | 14 | |
SNDX | SYNDAX PHARMACEUTICALS... | 14 | 14 | 0.07% | 1.54% | 3.20% | Q2 2020 | Q3 2023 | 14 |
MREO | MEREO BIOPHARMA GROUP PLC | 14 | 14 | 0.07% | 0.43% | 1.00% | Q2 2020 | Q3 2023 | 14 |
NEOS | NEOS THERAPEUTICS INC | 14 | 14 | 0.02% | 0.39% | 1.32% | Q3 2015 | Q4 2018 | 14 |
LRMR | LARIMAR THERAPEUTICS INC | 14 | 14 | 0.03% | 0.30% | 0.55% | Q2 2020 | Q3 2023 | 14 |
SPRO | SPERO THERAPEUTICS INC | 5 | 1 | 0.03% | 0.17% | 0.39% | Q4 2017 | Q3 2023 | 14 |
LCTX | LINEAGE CELL THERAPEUT... | 7 | 7 | 0.02% | 0.04% | 0.06% | Q3 2019 | Q2 2023 | 14 |
IDYA | IDEAYA BIOSCIENCES INC | 13 | 13 | 1.35% | 2.24% | 4.20% | Q3 2020 | Q3 2023 | 13 |
ISEE | IVERIC BIO INC | 13 | 13 | 0.13% | 1.75% | 6.59% | Q2 2020 | Q2 2023 | 13 |
ACET | ADICET BIO INC | 13 | 13 | 0.26% | 1.65% | 3.72% | Q3 2020 | Q3 2023 | 13 |
ARQL | ARQULE INC | 13 | 13 | 0.30% | 1.04% | 3.41% | Q4 2016 | Q4 2019 | 13 |
QURE | UNIQURE NV | 13 | 13 | 0.30% | 0.85% | 1.63% | Q3 2014 | Q3 2017 | 13 |
APLS | APELLIS PHARMACEUTICAL... | 8 | 5 | 0.17% | 0.81% | 1.54% | Q3 2019 | Q1 2023 | 13 |
CGNT | COGENTIX MEDICAL INC | 13 | 13 | 0.27% | 0.47% | 0.62% | Q1 2015 | Q1 2018 | 13 |
RVMD | REVOLUTION MEDICINES INC | 12 | 12 | 0.26% | 2.22% | 4.08% | Q4 2020 | Q3 2023 | 12 |
ARGX | ARGENX SE | 12 | 12 | 0.25% | 1.47% | 3.24% | Q2 2017 | Q1 2020 | 12 |
CDTX | CIDARA THERAPEUTICS INC | 12 | 12 | 0.04% | 0.62% | 1.46% | Q4 2016 | Q3 2019 | 12 |
NERV | MINERVA NEUROSCIENCES INC | 9 | 1 | 0.09% | 0.55% | 1.74% | Q1 2015 | Q1 2019 | 12 |
AUTL | AUTOLUS THERAPEUTICS PLC | 7 | 5 | 0.29% | 0.51% | 0.67% | Q2 2019 | Q3 2023 | 12 |
KNTE | KINNATE BIOPHARMA INC | 12 | 12 | 0.05% | 0.37% | 0.81% | Q4 2020 | Q3 2023 | 12 |
DSCO | DISCOVERY LABORATORIES... | 11 | 11 | 1.42% | 6.20% | 13.20% | Q2 2013 | Q4 2015 | 11 |
NRIX | NURIX THERAPEUTICS INC | 11 | 11 | 1.36% | 1.88% | 2.44% | Q1 2021 | Q3 2023 | 11 |
MRUS | MERUS N V | 11 | 11 | 0.70% | 1.62% | 3.56% | Q1 2021 | Q3 2023 | 11 |
WVE | WAVE LIFE SCIENCES LTD | 8 | 3 | 0.10% | 1.05% | 3.19% | Q1 2018 | Q2 2022 | 11 |
NUVASIVE INC | 11 | 11 | 0.72% | 1.03% | 1.44% | Q2 2013 | Q4 2015 | 11 | |
CRDC | CARDICA INC | 11 | 11 | 0.19% | 1.01% | 1.73% | Q2 2013 | Q4 2015 | 11 |
APPY | VENAXIS INC | 11 | 11 | 0.16% | 0.75% | 1.39% | Q2 2013 | Q4 2015 | 11 |
ETNB | 89BIO INC | 11 | 11 | 0.12% | 0.65% | 1.16% | Q2 2020 | Q4 2022 | 11 |
BWAY | BRAINWAY LTD | 11 | 11 | 0.15% | 0.35% | 0.54% | Q1 2021 | Q3 2023 | 11 |
OBSV | OBSEVA SA | 11 | 11 | 0.04% | 0.24% | 0.46% | Q1 2017 | Q3 2019 | 11 |
ADAP | ADAPTIMMUNE THERAPEUTI... | 8 | 3 | 0.08% | 0.21% | 0.62% | Q4 2015 | Q3 2023 | 11 |
GNVC | GENVEC INC | 11 | 11 | 0.03% | 0.18% | 0.33% | Q1 2014 | Q3 2016 | 11 |
PLX | PROTALIX BIOTHERAPEUTI... | 10 | 10 | 1.40% | 3.58% | 6.24% | Q2 2013 | Q3 2015 | 10 |
BGNE | BEIGENE LTD | 10 | 10 | 0.14% | 1.96% | 4.62% | Q1 2016 | Q2 2018 | 10 |
BSTC | BIOSPECIFICS TECHNOLOGIES | 7 | 3 | 1.02% | 1.37% | 2.14% | Q2 2013 | Q3 2016 | 10 |
XNPT | XENOPORT INC | 10 | 10 | 0.64% | 1.27% | 2.75% | Q2 2013 | Q3 2015 | 10 |
TNDM | TANDEM DIABETES CARE INC | 10 | 10 | 0.27% | 1.03% | 3.86% | Q1 2015 | Q2 2017 | 10 |
TBIO | TRANSLATE BIO INC | 4 | 3 | 0.12% | 0.94% | 2.17% | Q2 2018 | Q2 2021 | 10 |
IPSC | CENTURY THERAPEUTICS INC | 10 | 10 | 0.40% | 0.86% | 1.36% | Q2 2021 | Q3 2023 | 10 |
ICPT | INTERCEPT PHARMACEUTIC... | 10 | 10 | 0.40% | 0.75% | 2.70% | Q2 2013 | Q3 2015 | 10 |
ADXS | ADVAXIS INC | 9 | 1 | 0.05% | 0.64% | 1.19% | Q3 2015 | Q4 2018 | 10 |
TPTX | TURNING POINT THERAPEU... | 6 | 4 | 0.24% | 0.63% | 0.99% | Q3 2019 | Q2 2022 | 10 |
CRBP | CORBUS PHARMACEUTICALS... | 7 | 1 | 0.08% | 0.63% | 1.63% | Q2 2015 | Q2 2020 | 10 |
MEIP | MEI PHARMA INC | 10 | 10 | 0.07% | 0.46% | 1.18% | Q2 2020 | Q3 2022 | 10 |
ASLN | ASLAN PHARMACEUTICALS LTD | 6 | 4 | 0.04% | 0.19% | 0.54% | Q4 2019 | Q2 2022 | 10 |
GNFT | GENFIT S A | 10 | 10 | 0.08% | 0.18% | 0.24% | Q4 2020 | Q1 2023 | 10 |
BLCM | BELLICUM PHARMACEUTICA... | 6 | 4 | 0.02% | 0.10% | 0.21% | Q1 2017 | Q3 2019 | 10 |
SNSS | SUNESIS PHARMACEUTICAL... | 8 | 1 | 0.25% | 1.36% | 3.61% | Q4 2016 | Q3 2019 | 9 |
MRTX | MIRATI THERAPEUTICS INC | 7 | 2 | 0.72% | 1.08% | 1.46% | Q1 2020 | Q3 2023 | 9 |
INTEC PHARMA LTD JERUS... | 5 | 4 | 0.42% | 0.91% | 1.74% | Q3 2015 | Q2 2019 | 9 | |
RTIX | RTI SURGICAL INC | 9 | 9 | 0.33% | 0.56% | 0.92% | Q2 2013 | Q2 2015 | 9 |
ITOS | ITEOS THERAPEUTICS INC | 9 | 9 | 0.34% | 0.52% | 0.75% | Q3 2021 | Q3 2023 | 9 |
HARP | HARPOON THERAPEUTICS INC | 9 | 9 | 0.14% | 0.39% | 0.71% | Q1 2020 | Q1 2022 | 9 |
AERIE PHARMACEUTICALS INC | 9 | 9 | 0.31% | 0.36% | 0.41% | Q3 2020 | Q3 2022 | 9 | |
ASMB | ASSEMBLY BIOSCIENCES INC | 9 | 9 | 0.16% | 0.28% | 0.57% | Q3 2018 | Q3 2020 | 9 |
URGN | UROGEN PHARMA LTD | 9 | 9 | 0.02% | 0.18% | 0.32% | Q1 2018 | Q1 2020 | 9 |
PCYC | PHARMACYCLICS INC | 8 | 8 | 9.53% | 12.05% | 15.42% | Q2 2013 | Q1 2015 | 8 |
ESSA PHARMA INC | 8 | 8 | 0.25% | 0.95% | 2.22% | Q1 2015 | Q4 2016 | 8 | |
AXGN | AXOGEN INC | 8 | 8 | 0.69% | 0.93% | 1.46% | Q4 2021 | Q3 2023 | 8 |
CYTR | CYTRX CORP | 8 | 8 | 0.58% | 0.92% | 1.38% | Q1 2014 | Q4 2015 | 8 |
CUTR | CUTERA INC | 8 | 8 | 0.23% | 0.82% | 1.14% | Q2 2013 | Q1 2015 | 8 |
GLMD | GALMED PHARMACEUTICALS... | 4 | 1 | 0.04% | 0.76% | 1.99% | Q1 2014 | Q2 2018 | 8 |
VERO | VENUS CONCEPT INC | 8 | 8 | 0.12% | 0.50% | 0.77% | Q4 2020 | Q3 2022 | 8 |
IRONWOOD PHARMACEUTICA... | 8 | 8 | 0.33% | 0.48% | 0.61% | Q2 2016 | Q1 2018 | 8 | |
CYNAPSUS THERAPEUTICS ... | 8 | 8 | 0.15% | 0.38% | 0.53% | Q3 2014 | Q2 2016 | 8 | |
ZFGN | ZAFGEN INC | 8 | 8 | 0.08% | 0.27% | 0.78% | Q2 2018 | Q1 2020 | 8 |
NGM | NGM BIOPHARMACEUTICALS... | 7 | 1 | 0.04% | 0.25% | 0.43% | Q2 2019 | Q3 2022 | 8 |
CMPX | COMPASS THERAPEUTICS INC | 8 | 8 | 0.07% | 0.20% | 0.85% | Q4 2021 | Q3 2023 | 8 |
DEXCOM INC | 8 | 8 | 0.14% | 0.17% | 0.29% | Q2 2018 | Q1 2020 | 8 | |
CEMI | CHEMBIO DIAGNOSTICS INC | 8 | 8 | 0.08% | 0.14% | 0.21% | Q4 2013 | Q3 2015 | 8 |
CHEKW | CHECK CAP LTD-CW20 | 8 | 8 | 0.00% | 0.03% | 0.08% | Q1 2015 | Q4 2016 | 8 |
XBI | SPDR SP BIOTECH ETF | 7 | 7 | 6.31% | 11.82% | 13.23% | Q1 2022 | Q3 2023 | 7 |
EWTX | EDGEWISE THERAPEUTICS INC | 7 | 7 | 0.90% | 1.41% | 2.07% | Q1 2022 | Q3 2023 | 7 |
MNLO | MENLO THERAPEUTICS INC | 7 | 7 | 1.11% | 1.38% | 2.03% | Q2 2018 | Q4 2019 | 7 |
AGLE | AEGLEA BIOTHERAPEUTICS... | 7 | 7 | 0.96% | 1.36% | 2.21% | Q2 2016 | Q4 2017 | 7 |
SGYPQ | SYNERGY PHARMACEUTICALS | 7 | 7 | 0.18% | 1.17% | 2.23% | Q2 2015 | Q4 2016 | 7 |
CRIS | CURIS INC | 6 | 1 | 0.21% | 1.00% | 2.58% | Q2 2013 | Q1 2015 | 7 |
FSTX | F-STAR THERAPEUTICS INC | 7 | 7 | 0.64% | 0.99% | 1.35% | Q2 2021 | Q4 2022 | 7 |
UPI | UROPLASTY INC | 7 | 7 | 0.79% | 0.97% | 1.22% | Q2 2013 | Q4 2014 | 7 |
NSPR | INSPIREMD INC | 7 | 7 | 0.04% | 0.86% | 2.31% | Q2 2013 | Q4 2014 | 7 |
CYAD | CELYAD | 4 | 3 | 0.20% | 0.84% | 1.46% | Q2 2015 | Q1 2017 | 7 |
BCYC | BICYCLE THERAPEUTICS PLC | 7 | 7 | 0.60% | 0.77% | 1.02% | Q1 2022 | Q3 2023 | 7 |
CDNA | CAREDX INC | 7 | 7 | 0.50% | 0.61% | 0.80% | Q3 2014 | Q1 2016 | 7 |
NEURODERM LTD | 7 | 7 | 0.02% | 0.53% | 0.92% | Q1 2016 | Q3 2017 | 7 | |
HOOK | HOOKIPA PHARMA INC | 7 | 7 | 0.07% | 0.51% | 1.10% | Q2 2020 | Q4 2021 | 7 |
PARDES BIOSCIENCES INC | 7 | 7 | 0.19% | 0.43% | 0.96% | Q4 2021 | Q2 2023 | 7 | |
VIGIL NEUROSCIENCE INC | 7 | 7 | 0.07% | 0.37% | 0.59% | Q1 2022 | Q3 2023 | 7 | |
PRVL | PREVAIL THERAPEUTICS INC | 7 | 7 | 0.25% | 0.37% | 0.52% | Q2 2019 | Q4 2020 | 7 |
INOTEK PHARMACEUTICALS... | 7 | 7 | 0.24% | 0.35% | 0.55% | Q3 2016 | Q1 2018 | 7 | |
SURF | SURFACE ONCOLOGY INC | 7 | 7 | 0.18% | 0.34% | 0.52% | Q4 2021 | Q2 2023 | 7 |
GMDA | GAMIDA CELL LTD | 6 | 1 | 0.18% | 0.29% | 0.52% | Q2 2019 | Q3 2022 | 7 |
SCPH | SCPHARMACEUTICALS INC | 5 | 2 | 0.05% | 0.23% | 0.64% | Q4 2017 | Q2 2021 | 7 |
ALDX | ALDEYRA THERAPEUTICS INC | 4 | 1 | 0.01% | 0.22% | 0.64% | Q1 2015 | Q3 2019 | 7 |
SCYX | SCYNEXIS INC | 5 | 2 | 0.07% | 0.21% | 0.46% | Q4 2020 | Q4 2022 | 7 |
BTX | BIOTIME INC | 7 | 7 | 0.04% | 0.14% | 0.32% | Q4 2017 | Q2 2019 | 7 |
CYNA | CYNAPSUS THERAPEUTICS INC | 6 | 6 | 0.56% | 2.13% | 6.45% | Q2 2015 | Q3 2016 | 6 |
THLD | THRESHOLD PHARMACEUTICALS | 6 | 6 | 1.11% | 1.54% | 2.02% | Q4 2013 | Q1 2015 | 6 |
OCRX | OCERA THERAPEUTICS INC | 6 | 6 | 0.07% | 1.53% | 3.34% | Q3 2013 | Q4 2014 | 6 |
VBIV | VBI VACCINES INC | 6 | 6 | 0.68% | 1.25% | 2.30% | Q4 2017 | Q1 2019 | 6 |
CLVS | CLOVIS ONCOLOGY INC | 4 | 2 | 0.75% | 1.22% | 1.72% | Q4 2013 | Q2 2015 | 6 |
ARCT | ARCTURUS THERAPEUTICS ... | 6 | 6 | 0.01% | 1.14% | 3.20% | Q2 2019 | Q3 2020 | 6 |
DICE THERAPEUTICS INC | 6 | 6 | 0.43% | 0.98% | 1.62% | Q1 2022 | Q2 2023 | 6 | |
KERX | KERYX BIOPHARMACEUTICALS | 5 | 1 | 0.34% | 0.90% | 1.46% | Q2 2013 | Q1 2015 | 6 |
INSULET CORP | 6 | 6 | 0.78% | 0.80% | 0.83% | Q4 2017 | Q1 2019 | 6 | |
NVRO | NEVRO CORP | 4 | 2 | 0.17% | 0.52% | 0.84% | Q4 2018 | Q3 2023 | 6 |
ABEO | ABEONA THERAPEUTICS INC | 4 | 2 | 0.29% | 0.44% | 0.73% | Q3 2015 | Q1 2017 | 6 |
LPTX | LEAP THERPEUTICS INC | 5 | 1 | 0.17% | 0.43% | 0.81% | Q4 2017 | Q2 2020 | 6 |
KROS | KEROS THERAPEUTICS INC | 6 | 6 | 0.25% | 0.43% | 0.65% | Q2 2022 | Q3 2023 | 6 |
ATHA | ATHIRA PHARMA INC | 6 | 6 | 0.17% | 0.40% | 0.57% | Q4 2020 | Q1 2022 | 6 |
REGULUS THERAPEUTICS INC | 6 | 6 | 0.14% | 0.31% | 0.47% | Q2 2022 | Q3 2023 | 6 | |
LMNS | LUMENIS LTD | 6 | 6 | 0.09% | 0.28% | 0.43% | Q2 2014 | Q3 2015 | 6 |
CHEK | CHECK CAP LTD | 6 | 6 | 0.10% | 0.26% | 0.46% | Q1 2015 | Q2 2016 | 6 |
PIRS | PIERIS PHARMACEUTICALS... | 5 | 1 | 0.08% | 0.22% | 0.29% | Q2 2015 | Q1 2017 | 6 |
THESEUS PHARMACEUTICAL... | 6 | 6 | 0.12% | 0.21% | 0.35% | Q4 2021 | Q1 2023 | 6 | |
SLGL | SOL GEL TECHNOLOGIES LTD | 6 | 6 | 0.10% | 0.12% | 0.18% | Q1 2018 | Q2 2019 | 6 |
NVLS | NIVALIS THERAPEUTICS INC | 6 | 6 | 0.05% | 0.11% | 0.19% | Q2 2015 | Q3 2016 | 6 |
ALDER BIOPHARMACEUTICA... | 6 | 6 | 0.09% | 0.11% | 0.12% | Q1 2018 | Q2 2019 | 6 | |
CVM | CEL SCI CORP | 6 | 6 | 0.03% | 0.07% | 0.18% | Q2 2015 | Q3 2016 | 6 |
ABBV | ABBVIE INC | 5 | 5 | 3.75% | 5.71% | 6.62% | Q2 2015 | Q2 2016 | 5 |
AMPE | AMPIO PHARMACEUTICALS INC | 5 | 5 | 0.54% | 5.42% | 11.09% | Q3 2013 | Q3 2014 | 5 |
VTAE | VITAE PHARMACEUTICALS INC | 5 | 5 | 0.77% | 4.89% | 10.43% | Q3 2015 | Q3 2016 | 5 |
NVAX | NOVAVAX INC | 2 | 1 | 0.47% | 1.47% | 3.17% | Q3 2013 | Q3 2018 | 5 |
MRNS | MARINUS PHARMACEUTICAL... | 5 | 5 | 0.09% | 1.40% | 3.86% | Q2 2015 | Q2 2016 | 5 |
RGLS | REGULUS THERAPEUTICS INC | 5 | 5 | 0.58% | 1.11% | 2.34% | Q3 2015 | Q3 2016 | 5 |
ECIA | ENCISION INC | 5 | 5 | 0.49% | 0.78% | 1.07% | Q2 2014 | Q2 2015 | 5 |
BIOHAVEN LTD | 5 | 5 | 0.14% | 0.64% | 1.54% | Q3 2022 | Q3 2023 | 5 | |
EPZM | EPIZYME INC | 4 | 1 | 0.29% | 0.57% | 0.82% | Q1 2015 | Q1 2020 | 5 |
GNCA | GENOCEA BIOSCIENCES INC | 5 | 5 | 0.35% | 0.56% | 1.08% | Q2 2019 | Q2 2020 | 5 |
IMDZ | IMMUNE DESIGN CORP | 4 | 1 | 0.21% | 0.52% | 0.70% | Q3 2016 | Q3 2018 | 5 |
COGT | COGENT BIOSCIENCES INC | 5 | 5 | 0.38% | 0.45% | 0.50% | Q1 2021 | Q1 2022 | 5 |
ABUS | ARBUTUS BIOPHARMA CORP | 2 | 1 | 0.21% | 0.39% | 0.50% | Q1 2016 | Q1 2019 | 5 |
ADMP | ADAMIS PHARMACEUTICALS... | 3 | 2 | 0.08% | 0.36% | 0.82% | Q4 2013 | Q3 2017 | 5 |
LPTN | LPATH INC | 5 | 5 | 0.21% | 0.33% | 0.43% | Q1 2014 | Q1 2015 | 5 |
ALPN | ALPINE IMMUNE SCIENCES... | 5 | 5 | 0.21% | 0.33% | 0.42% | Q3 2020 | Q3 2021 | 5 |
BMEA | BIOMEA FUSION INC | 5 | 5 | 0.08% | 0.33% | 0.59% | Q4 2021 | Q4 2022 | 5 |
SYROS PHARMACEUTICALS INC | 5 | 5 | 0.21% | 0.30% | 0.46% | Q3 2022 | Q3 2023 | 5 | |
INFI | INFINITY PHARMACEUTICA... | 5 | 5 | 0.04% | 0.20% | 0.35% | Q1 2021 | Q1 2022 | 5 |
LVTX | LAVA THERAPEUTICS NV | 5 | 5 | 0.10% | 0.20% | 0.31% | Q2 2021 | Q2 2022 | 5 |
TNXP | TONIX PHARMACEUTICALS ... | 3 | 1 | 0.07% | 0.20% | 0.34% | Q3 2013 | Q1 2015 | 5 |
CTMX | CYTOMX THERAPEUTICS INC | 4 | 1 | 0.02% | 0.19% | 0.32% | Q3 2017 | Q2 2020 | 5 |
BDTX | BLACK DIAMOND THERAPEU... | 5 | 5 | 0.05% | 0.18% | 0.28% | Q4 2021 | Q4 2022 | 5 |
CBIO | CATALYST BIOSCIENCES INC | 5 | 5 | 0.06% | 0.15% | 0.33% | Q3 2015 | Q3 2016 | 5 |
GRTS | GRITSTONE ONCOLOGY INC | 5 | 5 | 0.10% | 0.15% | 0.21% | Q2 2019 | Q2 2020 | 5 |
ATRS | ANTARES PHARMA INC | 5 | 5 | 0.03% | 0.06% | 0.08% | Q2 2015 | Q2 2016 | 5 |
INSULET CORP | 4 | 4 | 4.08% | 4.76% | 5.72% | Q2 2013 | Q1 2014 | 4 | |
BOTA | BIOTA PHARMACEUTICALS INC | 4 | 4 | 0.92% | 2.03% | 3.83% | Q3 2013 | Q2 2014 | 4 |
VYGR | VOYAGER THERAPEUTICS INC | 4 | 4 | 0.80% | 1.25% | 1.50% | Q1 2017 | Q4 2017 | 4 |
DERMIRA INC | 4 | 4 | 0.58% | 0.92% | 1.19% | Q2 2017 | Q1 2018 | 4 | |
ITEK | INOTEK PHARMACEUTICALS... | 4 | 4 | 0.32% | 0.89% | 1.57% | Q3 2016 | Q2 2017 | 4 |
TRGT | TARGACEPT INC | 4 | 4 | 0.34% | 0.87% | 1.09% | Q3 2014 | Q2 2015 | 4 |
MEDIWOUND LTD | 4 | 4 | 0.75% | 0.85% | 1.03% | Q4 2022 | Q3 2023 | 4 | |
LQDA | LIQUIDIA TECHNOLOGIES INC | 4 | 4 | 0.37% | 0.78% | 1.34% | Q2 2020 | Q1 2021 | 4 |
ELOX | ELOXX PHARMACEUTICALS INC | 4 | 4 | 0.16% | 0.68% | 1.40% | Q2 2019 | Q1 2020 | 4 |
INCY | INCYTE CORP | 4 | 4 | 0.61% | 0.64% | 0.68% | Q1 2018 | Q4 2018 | 4 |
LPCN | LIPOCINE INC | 4 | 4 | 0.53% | 0.64% | 0.84% | Q2 2015 | Q1 2016 | 4 |
AQXP | AQUINOX PHARMACEUTICAL... | 3 | 1 | 0.19% | 0.59% | 0.75% | Q3 2016 | Q1 2018 | 4 |
CNCE | CONCERT PHARMACEUTICAL... | 3 | 1 | 0.47% | 0.58% | 0.66% | Q2 2016 | Q4 2018 | 4 |
TARGACEPT INC | 4 | 4 | 0.42% | 0.47% | 0.53% | Q3 2015 | Q2 2016 | 4 | |
IRONWOOD PHARMA | 4 | 4 | 0.34% | 0.46% | 0.53% | Q2 2015 | Q1 2016 | 4 | |
FIELD TRIP HEALTH LTD | 4 | 4 | 0.21% | 0.46% | 0.76% | Q3 2021 | Q2 2022 | 4 | |
EIGR | EIGER BIOPHARMACEUTICA... | 4 | 4 | 0.20% | 0.45% | 0.84% | Q3 2016 | Q2 2017 | 4 |
ORIC | ORIC PHARMACEUTICALS INC | 4 | 4 | 0.29% | 0.40% | 0.51% | Q2 2022 | Q1 2023 | 4 |
VTVT | VTV THERAPEUTICS INC- ... | 4 | 4 | 0.32% | 0.40% | 0.48% | Q3 2015 | Q2 2016 | 4 |
CASC | CASCADIAN THERAPEUTICS... | 4 | 4 | 0.21% | 0.37% | 0.65% | Q1 2017 | Q4 2017 | 4 |
SYBX | SYNLOGIC INC | 4 | 4 | 0.24% | 0.35% | 0.44% | Q3 2019 | Q2 2020 | 4 |
PTN | PALATIN TECHNOLOGIES INC | 3 | 1 | 0.11% | 0.28% | 0.47% | Q2 2013 | Q3 2016 | 4 |
CMPS | COMPASS PATHWAYS PLC | 3 | 1 | 0.14% | 0.26% | 0.44% | Q1 2022 | Q3 2023 | 4 |
CLTX | CELSUS THERAPEUTICS PLC | 4 | 4 | 0.17% | 0.24% | 0.27% | Q1 2014 | Q4 2014 | 4 |
EDGE | EDGE THERAPEUTICS INC | 3 | 1 | 0.10% | 0.23% | 0.55% | Q1 2016 | Q4 2017 | 4 |
AKTX | AKARI THERAPEUTICS PLC | 4 | 4 | 0.01% | 0.20% | 0.63% | Q3 2015 | Q2 2016 | 4 |
TENX | TENAX THERAPEUTICS INC | 4 | 4 | 0.14% | 0.19% | 0.24% | Q3 2015 | Q2 2016 | 4 |
ACRIVON THERAPEUTICS INC | 4 | 4 | 0.05% | 0.19% | 0.27% | Q4 2022 | Q3 2023 | 4 | |
SRRA | SIERRA ONCOLOGY INC | 3 | 1 | 0.04% | 0.17% | 0.34% | Q1 2017 | Q1 2018 | 4 |
ATNM | ACTINIUM PHARMACEUTICA... | 3 | 1 | 0.12% | 0.16% | 0.20% | Q1 2015 | Q3 2017 | 4 |
KPTI | KARYOPHARM THERAPEUTIC... | 4 | 4 | 0.08% | 0.15% | 0.22% | Q4 2022 | Q3 2023 | 4 |
DEXCOM INC | 4 | 4 | 0.12% | 0.14% | 0.18% | Q2 2017 | Q1 2018 | 4 | |
SRGA | SURGALIGN HOLDINGS INC | 4 | 4 | 0.05% | 0.12% | 0.17% | Q2 2021 | Q1 2022 | 4 |
MDNA | MEDICENNA THERAPEUTICS... | 4 | 4 | 0.08% | 0.11% | 0.15% | Q3 2022 | Q2 2023 | 4 |
ALRN | AILERON THERAPEUTICS INC | 3 | 1 | 0.02% | 0.07% | 0.15% | Q1 2019 | Q2 2020 | 4 |
ANNX | ANNEXON INC | 4 | 4 | 0.02% | 0.07% | 0.12% | Q3 2021 | Q2 2022 | 4 |
RVP | RETRACTABLE TECHNOLOGI... | 4 | 4 | 0.05% | 0.06% | 0.06% | Q4 2013 | Q3 2014 | 4 |
ORMP | ORAMED PHARMACEUTICALS... | 4 | 4 | 0.02% | 0.03% | 0.04% | Q4 2018 | Q3 2019 | 4 |
ASPX | AUSPEX PHARMACEUTICALS... | 3 | 3 | 3.94% | 6.28% | 9.28% | Q3 2014 | Q1 2015 | 3 |
GIVN | GIVEN IMAGING LTD | 3 | 3 | 3.20% | 3.78% | 4.84% | Q2 2013 | Q4 2013 | 3 |
ZSPH | ZS PHARMA INC | 3 | 3 | 1.26% | 2.85% | 4.31% | Q1 2015 | Q3 2015 | 3 |
TSRO | TESARO INC | 3 | 3 | 1.83% | 1.96% | 2.06% | Q2 2016 | Q4 2016 | 3 |
MACK | MERRIMACK PHARMACEUTIC... | 3 | 3 | 0.75% | 1.62% | 2.23% | Q3 2013 | Q1 2014 | 3 |
DYAX | DYAX CORP | 3 | 3 | 0.57% | 1.36% | 2.93% | Q2 2013 | Q4 2013 | 3 |
NEOT | NEOTHETICS INC | 3 | 3 | 1.10% | 1.23% | 1.40% | Q4 2014 | Q2 2015 | 3 |
CNST | CONSTELLATION PHARMACE... | 3 | 3 | 0.86% | 1.18% | 1.48% | Q2 2020 | Q4 2020 | 3 |
AAVL | AVALANCHE BIOTECHNOLOG... | 3 | 3 | 0.63% | 0.99% | 1.19% | Q3 2015 | Q1 2016 | 3 |
TBRA | TOBIRA THERAPEUTICS INC | 3 | 3 | 0.43% | 0.82% | 1.44% | Q3 2015 | Q1 2016 | 3 |
CNAT | CONATUS PHARMACEUTICAL... | 2 | 1 | 0.21% | 0.79% | 1.27% | Q3 2013 | Q2 2017 | 3 |
TNDM | TANDEM DIABETES CARE INC | 2 | 1 | 0.14% | 0.77% | 1.43% | Q1 2018 | Q3 2023 | 3 |
FSII | FS DEVELOPMENT CORP II | 3 | 3 | 0.63% | 0.71% | 0.79% | Q1 2021 | Q3 2021 | 3 |
AXGT | AXOVANT SCIENCES LTD | 3 | 3 | 0.26% | 0.70% | 1.04% | Q1 2020 | Q3 2020 | 3 |
ARNA | ARENA PHARMACEUTICALS INC | 3 | 3 | 0.65% | 0.70% | 0.74% | Q2 2015 | Q4 2015 | 3 |
BAXSQ | BAXANO SURGICAL INC | 3 | 3 | 0.35% | 0.68% | 1.18% | Q2 2013 | Q4 2013 | 3 |
CMTA | CLEMENTIA PHARMACEUTIC... | 3 | 3 | 0.61% | 0.67% | 0.77% | Q3 2017 | Q1 2018 | 3 |
TRVN | TREVENA INC | 2 | 1 | 0.14% | 0.54% | 1.32% | Q4 2014 | Q4 2015 | 3 |
RDHL | REDHILL BIOPHARMA LTD | 2 | 1 | 0.10% | 0.52% | 0.79% | Q4 2017 | Q2 2021 | 3 |
IFRX | INFLARX NV | 3 | 3 | 0.37% | 0.45% | 0.56% | Q1 2021 | Q3 2021 | 3 |
ASTRIA THERAPEUTICS INC | 3 | 3 | 0.28% | 0.42% | 0.69% | Q1 2023 | Q3 2023 | 3 | |
PTI | PROTEOSTASIS THERAPEUT... | 2 | 1 | 0.09% | 0.36% | 0.62% | Q4 2017 | Q4 2018 | 3 |
GEMP | GEMPHIRE THERAPEUTICS INC | 2 | 1 | 0.28% | 0.36% | 0.47% | Q1 2017 | Q1 2018 | 3 |
NMUS | NEMUS BIOSCIENCE INC | 3 | 3 | 0.20% | 0.28% | 0.34% | Q4 2015 | Q2 2016 | 3 |
ZYME | ZYMEWORKS INC | 3 | 3 | 0.15% | 0.27% | 0.47% | Q1 2020 | Q3 2020 | 3 |
SPRB | SPRUCE BIOSCIENCES INC | 3 | 3 | 0.18% | 0.26% | 0.40% | Q1 2023 | Q3 2023 | 3 |
BOLT | BOLT BIOTHERAPEUTICS INC | 3 | 3 | 0.12% | 0.26% | 0.34% | Q2 2021 | Q4 2021 | 3 |
INSM | INSMED INC | 3 | 3 | 0.20% | 0.24% | 0.29% | Q2 2019 | Q4 2019 | 3 |
VRNA | VERONA PHARMA PLC | 3 | 3 | 0.04% | 0.23% | 0.34% | Q3 2020 | Q1 2021 | 3 |
ADXS | ADVAXIS INC | 2 | 1 | 0.04% | 0.22% | 0.52% | Q1 2019 | Q4 2019 | 3 |
BLFS | BIOLIFE SOLUTIONS INC | 3 | 3 | 0.15% | 0.22% | 0.25% | Q2 2014 | Q4 2014 | 3 |
ONTY | ONCOTHYREON INC | 2 | 1 | 0.10% | 0.21% | 0.42% | Q3 2014 | Q3 2015 | 3 |
GHRS | GH RESEARCH PLC | 3 | 3 | 0.15% | 0.19% | 0.26% | Q1 2022 | Q3 2022 | 3 |
APTX | APTINYX INC | 3 | 3 | 0.12% | 0.19% | 0.28% | Q2 2018 | Q4 2018 | 3 |
APTOSE BIOSCIENCES INC | 3 | 3 | 0.08% | 0.16% | 0.30% | Q1 2015 | Q3 2015 | 3 | |
PHVS | PHARVARIS N V | 3 | 3 | 0.13% | 0.15% | 0.16% | Q3 2021 | Q1 2022 | 3 |
SBPH | SPRING BK PHARMACEUTIC... | 2 | 1 | 0.07% | 0.14% | 0.19% | Q4 2016 | Q3 2017 | 3 |
DNAI | PRONAI THERAPEUTICS INC | 3 | 3 | 0.06% | 0.12% | 0.17% | Q3 2015 | Q1 2016 | 3 |
IKNA | IKENA ONCOLOGY INC | 3 | 3 | 0.09% | 0.11% | 0.12% | Q3 2022 | Q1 2023 | 3 |
CASM | CAS MEDICAL SYSTEMS INC | 3 | 3 | 0.10% | 0.10% | 0.11% | Q1 2015 | Q3 2015 | 3 |
BPMX | BIOPHARMX CORP | 2 | 1 | 0.02% | 0.07% | 0.14% | Q1 2016 | Q1 2017 | 3 |
GBIM | GLOBEIMMUNE INC | 3 | 3 | 0.05% | 0.06% | 0.08% | Q3 2014 | Q1 2015 | 3 |
CNTB | CONNECT BIOPHARMA HLDG... | 2 | 1 | 0.03% | 0.04% | 0.06% | Q1 2021 | Q2 2022 | 3 |
GALE | GALENA BIOPHARMA INC C... | 3 | 3 | 0.01% | 0.02% | 0.02% | Q1 2017 | Q3 2017 | 3 |
REUNION NEUROSCIENCE INC | 3 | 3 | 0.00% | 0.02% | 0.04% | Q3 2022 | Q1 2023 | 3 | |
ETRM | ENTEROMEDICS INC COM P... | 3 | 3 | 0.00% | 0.01% | 0.03% | Q1 2016 | Q3 2016 | 3 |
CBMXW | COMBIMATRIX CORP | 3 | 3 | 0.00% | 0.00% | 0.00% | Q2 2013 | Q4 2013 | 3 |
ARIA | ARIAD PHARMACEUTICALS INC | 2 | 2 | 2.99% | 3.94% | 4.89% | Q2 2013 | Q3 2013 | 2 |
CTIC | CTI BIOPHARMA CORP | 1 | 1 | 2.66% | 3.08% | 3.50% | Q4 2014 | Q4 2015 | 2 |
DAWN | DAY ONE BIOPHARMACEUTI... | 2 | 2 | 1.66% | 1.95% | 2.24% | Q2 2023 | Q3 2023 | 2 |
2SEVENTY BIO INC | 2 | 2 | 1.37% | 1.57% | 1.76% | Q2 2023 | Q3 2023 | 2 | |
CLLS | CELLECTIS S A | 2 | 2 | 1.41% | 1.48% | 1.55% | Q1 2017 | Q2 2017 | 2 |
PTGX | PROTAGONIST THERAPEUTI... | 2 | 2 | 0.88% | 1.35% | 1.82% | Q3 2016 | Q4 2016 | 2 |
TBPH | THERAVANCE BIOPHARMA INC | 2 | 2 | 0.20% | 1.21% | 2.22% | Q1 2021 | Q2 2021 | 2 |
ASCENDIS PHARMA A/S | 2 | 2 | 0.99% | 1.07% | 1.15% | Q2 2023 | Q3 2023 | 2 | |
LDRH | LDR HLDG CORP | 2 | 2 | 0.88% | 0.99% | 1.11% | Q1 2016 | Q2 2016 | 2 |
KBIO | KALOBIOS PHARMACEUTICA... | 2 | 2 | 0.66% | 0.95% | 1.23% | Q2 2013 | Q3 2013 | 2 |
WINT | WINDTREE THERAPEUTICS INC | 2 | 2 | 0.82% | 0.84% | 0.86% | Q2 2016 | Q3 2016 | 2 |
OPHT | OPHTHOTECH CORP | 1 | 1 | 0.09% | 0.79% | 1.50% | Q3 2016 | Q3 2017 | 2 |
ADHD | ALCOBRA LTD | 2 | 2 | 0.15% | 0.77% | 1.39% | Q1 2014 | Q2 2014 | 2 |
BLRX | BIOLINERX LTD | 2 | 2 | 0.59% | 0.70% | 0.81% | Q1 2017 | Q2 2017 | 2 |
CYNAPSUS THERAPEUTICS INC | 2 | 2 | 0.53% | 0.68% | 0.83% | Q4 2014 | Q1 2015 | 2 | |
GALE | GALENA BIOPHARMA INC | 1 | 1 | 0.27% | 0.60% | 0.93% | Q3 2013 | Q1 2015 | 2 |
ENDOLOGIX INC | 2 | 2 | 0.43% | 0.46% | 0.49% | Q4 2015 | Q1 2016 | 2 | |
RGLS | REGULUS THERAPEUTICS INC | 2 | 2 | 0.43% | 0.44% | 0.44% | Q4 2021 | Q1 2022 | 2 |
TGX | THERAGENICS CORP | 2 | 2 | 0.38% | 0.43% | 0.49% | Q2 2013 | Q3 2013 | 2 |
INNL | INNOCOLL HLDGS PLC | 2 | 2 | 0.40% | 0.42% | 0.44% | Q2 2016 | Q3 2016 | 2 |
SPPI | SPECTRUM PHARMACEUTICA... | 1 | 1 | 0.15% | 0.42% | 0.68% | Q3 2020 | Q1 2021 | 2 |
PROCEPT BIOROBOTICS CORP | 2 | 2 | 0.08% | 0.38% | 0.69% | Q2 2023 | Q3 2023 | 2 | |
IPCI | INTELLIPHARMACEUTICS I... | 2 | 2 | 0.22% | 0.36% | 0.50% | Q3 2014 | Q4 2014 | 2 |
TGTX | TG THERAPEUTICS INC | 2 | 2 | 0.30% | 0.36% | 0.41% | Q3 2013 | Q4 2013 | 2 |
CFMS | CONFORMIS INC | 2 | 2 | 0.30% | 0.31% | 0.31% | Q1 2021 | Q2 2021 | 2 |
AVEO | AVEO PHARMACEUTICALS INC | 1 | 1 | 0.20% | 0.27% | 0.34% | Q1 2014 | Q2 2016 | 2 |
GRMH | GRAYMARK HEALTHCARE INC | 2 | 2 | 0.21% | 0.26% | 0.31% | Q2 2013 | Q3 2013 | 2 |
NTGN | NEON THERAPEUICS INC | 2 | 2 | 0.18% | 0.24% | 0.30% | Q2 2018 | Q3 2018 | 2 |
TCRR | TCR2 THERAPEUTICS INC | 2 | 2 | 0.20% | 0.23% | 0.26% | Q1 2020 | Q2 2020 | 2 |
ARRY | ARRAY BIOPHARMA INC | 1 | 1 | 0.12% | 0.22% | 0.33% | Q3 2016 | Q2 2017 | 2 |
XCUR | EXICURE INC | 2 | 2 | 0.17% | 0.22% | 0.27% | Q4 2019 | Q1 2020 | 2 |
DXTRQ | DEXTERA SURGICAL INC | 2 | 2 | 0.18% | 0.19% | 0.20% | Q2 2016 | Q3 2016 | 2 |
SNSS | SUNESIS PHARMACEUTICAL... | 2 | 2 | 0.18% | 0.19% | 0.20% | Q1 2016 | Q2 2016 | 2 |
BTAI | BIOXCEL THERAPEUTICS INC | 1 | 1 | 0.04% | 0.19% | 0.34% | Q3 2019 | Q1 2020 | 2 |
DCPH | DECIPHERA PHARMACEUTIC... | 2 | 2 | 0.12% | 0.18% | 0.24% | Q3 2017 | Q4 2017 | 2 |
ADAT | AUTHENTIDATE HOLDING CORP | 2 | 2 | 0.14% | 0.16% | 0.18% | Q2 2013 | Q3 2013 | 2 |
ARCT | ARCTURUS THERAPEUTICS LTD | 2 | 2 | 0.14% | 0.15% | 0.16% | Q4 2018 | Q1 2019 | 2 |
NSPH | NANOSPHERE INC | 2 | 2 | 0.11% | 0.15% | 0.19% | Q4 2014 | Q1 2015 | 2 |
ELEV | ELEVATION ONCOLOGY INC | 2 | 2 | 0.09% | 0.14% | 0.19% | Q2 2023 | Q3 2023 | 2 |
TTHI | TRANSITION THERAPEUTIC... | 2 | 2 | 0.10% | 0.12% | 0.14% | Q1 2015 | Q2 2015 | 2 |
ANAB | ANAPTYSBIO INC | 2 | 2 | 0.09% | 0.10% | 0.11% | Q1 2017 | Q2 2017 | 2 |
ETRM | ENTEROMEDICS INC | 2 | 2 | 0.06% | 0.09% | 0.13% | Q3 2015 | Q4 2015 | 2 |
AVGR | AVINGER INC | 2 | 2 | 0.08% | 0.09% | 0.10% | Q3 2016 | Q4 2016 | 2 |
VBLT | VASCULAR BIOGENICS LTD | 2 | 2 | 0.03% | 0.09% | 0.15% | Q2 2021 | Q3 2021 | 2 |
EVLO | EVELO BIOSCIENCES INC | 2 | 2 | 0.02% | 0.03% | 0.05% | Q3 2019 | Q4 2019 | 2 |
BEAT | CARDIONET INC | 1 | 1 | 3.47% | 3.47% | 3.47% | Q2 2013 | Q2 2013 | 1 |
SGMO | SANGAMO THERAPEUTICS INC | 1 | 1 | 1.41% | 1.41% | 1.41% | Q2 2017 | Q2 2017 | 1 |
WRIGHT MED GROUP INC | 1 | 1 | 1.34% | 1.34% | 1.34% | Q3 2013 | Q3 2013 | 1 | |
PLX | PROTALIX BIOTHERAPEUTI... | 1 | 1 | 1.28% | 1.28% | 1.28% | Q1 2021 | Q1 2021 | 1 |
CRTX | CORTEXYME INC | 1 | 1 | 1.04% | 1.04% | 1.04% | Q2 2019 | Q2 2019 | 1 |
INFU | INFUSYSTEM HOLDINGS INC | 1 | 1 | 1.04% | 1.04% | 1.04% | Q2 2013 | Q2 2013 | 1 |
VRTX | VERTEX PHARMACEUTICALS... | 1 | 1 | 1.01% | 1.01% | 1.01% | Q2 2013 | Q2 2013 | 1 |
OGXI | ONCOGENEX PHARMACEUTIC... | 1 | 1 | 0.96% | 0.96% | 0.96% | Q4 2013 | Q4 2013 | 1 |
AKAOQ | ACHAOGEN INC COM | 1 | 1 | 0.94% | 0.94% | 0.94% | Q2 2016 | Q2 2016 | 1 |
CUR | NEURALSTEM INC | 1 | 1 | 0.92% | 0.92% | 0.92% | Q3 2013 | Q3 2013 | 1 |
SAVA | CASSAVA SCIENCES INC | 1 | 1 | 0.91% | 0.91% | 0.91% | Q4 2020 | Q4 2020 | 1 |
ZGNX | ZOGENIX INC | 1 | 1 | 0.90% | 0.90% | 0.90% | Q1 2015 | Q1 2015 | 1 |
ANAC | ANACOR PHARMACEUTICALS... | 1 | 1 | 0.88% | 0.88% | 0.88% | Q2 2013 | Q2 2013 | 1 |
MNOV | MEDICINOVA INC | 1 | 1 | 0.79% | 0.79% | 0.79% | Q1 2016 | Q1 2016 | 1 |
DSCO | DISCOVERY LABORATORIES... | 1 | 1 | 0.77% | 0.77% | 0.77% | Q1 2016 | Q1 2016 | 1 |
AMYLYX PHARMACEUTICALS... | 1 | 1 | 0.70% | 0.70% | 0.70% | Q3 2023 | Q3 2023 | 1 | |
ASTM | AASTROM BIOSCIENCES INC | 1 | 1 | 0.69% | 0.69% | 0.69% | Q3 2014 | Q3 2014 | 1 |
GERN | GERON CORP | 1 | 1 | 0.61% | 0.61% | 0.61% | Q2 2016 | Q2 2016 | 1 |
THIRD HARMONIC BIO INC | 1 | 1 | 0.60% | 0.60% | 0.60% | Q3 2023 | Q3 2023 | 1 | |
IMUC | IMMUNOCELLULAR THERAPE... | 1 | 1 | 0.59% | 0.59% | 0.59% | Q1 2014 | Q1 2014 | 1 |
ADMS | ADAMAS PHARMACEUTICALS... | 1 | 1 | 0.59% | 0.59% | 0.59% | Q1 2016 | Q1 2016 | 1 |
DVAX | DYNAVAX TECHNOLOGIES CORP | 1 | 1 | 0.58% | 0.58% | 0.58% | Q4 2013 | Q4 2013 | 1 |
CELG | CELGENE CORP | 1 | 1 | 0.56% | 0.56% | 0.56% | Q3 2015 | Q3 2015 | 1 |
GILD | GILEAD SCIENCES INC | 1 | 1 | 0.56% | 0.56% | 0.56% | Q3 2015 | Q3 2015 | 1 |
ABIO | ARCA BIOPHARMA INC | 1 | 1 | 0.55% | 0.55% | 0.55% | Q2 2015 | Q2 2015 | 1 |
MDWD | MEDIWOUND LTD | 1 | 1 | 0.53% | 0.53% | 0.53% | Q3 2022 | Q3 2022 | 1 |
ACAD | ACADIA PHARMACEUTICALS... | 1 | 1 | 0.51% | 0.51% | 0.51% | Q1 2021 | Q1 2021 | 1 |
AMGN | AMGEN INC | 1 | 1 | 0.51% | 0.51% | 0.51% | Q3 2015 | Q3 2015 | 1 |
GNCA | GENOCEA BIOSCIENCES INC | 1 | 1 | 0.51% | 0.51% | 0.51% | Q1 2019 | Q1 2019 | 1 |
FSDC | FS DEVELOPMENT CORP | 1 | 1 | 0.49% | 0.49% | 0.49% | Q4 2020 | Q4 2020 | 1 |
GMTX | GEMINI THERAPEUTICS INC | 1 | 1 | 0.48% | 0.48% | 0.48% | Q1 2021 | Q1 2021 | 1 |
CRDC | CARDICA INC COM | 1 | 1 | 0.43% | 0.43% | 0.43% | Q1 2016 | Q1 2016 | 1 |
CERE | CEREVEL THERAPEUTICS H... | 1 | 1 | 0.42% | 0.42% | 0.42% | Q3 2023 | Q3 2023 | 1 |
IMCR | IMMUNOCORE HOLDINGS PLC | 1 | 1 | 0.42% | 0.42% | 0.42% | Q1 2022 | Q1 2022 | 1 |
IMGN | IMMUNOGEN INC | 1 | 1 | 0.41% | 0.41% | 0.41% | Q3 2023 | Q3 2023 | 1 |
LYRA | LYRA THERAPEUTICS INC | 1 | 1 | 0.41% | 0.41% | 0.41% | Q2 2023 | Q2 2023 | 1 |
GOSS | GOSSAMER BIO INC | 1 | 1 | 0.38% | 0.38% | 0.38% | Q3 2023 | Q3 2023 | 1 |
IDRA | IDERA PHARMACEUTICALS INC | 1 | 1 | 0.38% | 0.38% | 0.38% | Q3 2013 | Q3 2013 | 1 |
ACRS | ACLARIS THERAPEUTICS INC | 1 | 1 | 0.37% | 0.37% | 0.37% | Q2 2021 | Q2 2021 | 1 |
CGEM | CULLINAN ONCOLOGY INC | 1 | 1 | 0.36% | 0.36% | 0.36% | Q3 2023 | Q3 2023 | 1 |
TTPH | TETRAPHASE PHARMACEUTI... | 1 | 1 | 0.35% | 0.35% | 0.35% | Q2 2016 | Q2 2016 | 1 |
ADVM | ADVERUM BIOTECHNOLOGIE... | 1 | 1 | 0.35% | 0.35% | 0.35% | Q2 2016 | Q2 2016 | 1 |
SVRA | SAVARA INC | 1 | 1 | 0.35% | 0.35% | 0.35% | Q1 2019 | Q1 2019 | 1 |
EYES | SECOND SIGHT MED PRODS... | 1 | 1 | 0.32% | 0.32% | 0.32% | Q4 2014 | Q4 2014 | 1 |
MLND | MILLENDO THERAPEUTICS INC | 1 | 1 | 0.30% | 0.30% | 0.30% | Q4 2019 | Q4 2019 | 1 |
SYN | SYNTHETIC BIOLOGICS INC | 1 | 1 | 0.29% | 0.29% | 0.29% | Q4 2013 | Q4 2013 | 1 |
IMVT | IMMUNOVANT INC | 1 | 1 | 0.27% | 0.27% | 0.27% | Q3 2023 | Q3 2023 | 1 |
PAND | PANDION THERAPEUTICS INC | 1 | 1 | 0.26% | 0.26% | 0.26% | Q4 2020 | Q4 2020 | 1 |
CERC | CERECOR INC | 1 | 1 | 0.24% | 0.24% | 0.24% | Q2 2020 | Q2 2020 | 1 |
SLNO | SOLENO THERAPEUTICS INC | 1 | 1 | 0.24% | 0.24% | 0.24% | Q2 2020 | Q2 2020 | 1 |
BIOL | BIOLASE INC | 1 | 1 | 0.23% | 0.23% | 0.23% | Q3 2013 | Q3 2013 | 1 |
DMAC | DIAMEDICA THERAPEUTICS... | 1 | 1 | 0.22% | 0.22% | 0.22% | Q3 2020 | Q3 2020 | 1 |
CHMA | CHIASMA INC | 1 | 1 | 0.21% | 0.21% | 0.21% | Q3 2020 | Q3 2020 | 1 |
VLRX | VALERITAS HOLDINGS INC | 1 | 1 | 0.21% | 0.21% | 0.21% | Q4 2018 | Q4 2018 | 1 |
PROBIODRUG AG | 1 | 1 | 0.19% | 0.19% | 0.19% | Q4 2014 | Q4 2014 | 1 | |
RGDO | REGADO BIOSCIENCES INC | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2014 | Q2 2014 | 1 |
CYCC | CYCLACEL PHARMACEUTICA... | 1 | 1 | 0.19% | 0.19% | 0.19% | Q2 2013 | Q2 2013 | 1 |
AXSM | AXSOME THERAPEUTICS INC | 1 | 1 | 0.18% | 0.18% | 0.18% | Q1 2017 | Q1 2017 | 1 |
BVX | BOVIE MEDICAL CORP | 1 | 1 | 0.18% | 0.18% | 0.18% | Q1 2015 | Q1 2015 | 1 |
ESSA PHARMA INC | 1 | 1 | 0.18% | 0.18% | 0.18% | Q4 2014 | Q4 2014 | 1 | |
APPY | VENAXIS INC | 1 | 1 | 0.17% | 0.17% | 0.17% | Q1 2016 | Q1 2016 | 1 |
BITI | BIOTIE THERAPIES | 1 | 1 | 0.17% | 0.17% | 0.17% | Q2 2015 | Q2 2015 | 1 |
CINCOR PHARMA INC | 1 | 1 | 0.17% | 0.17% | 0.17% | Q4 2022 | Q4 2022 | 1 | |
GLYC | GLYCOMIMETICS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q2 2016 | Q2 2016 | 1 |
STEM | STEMCELLS INC | 1 | 1 | 0.16% | 0.16% | 0.16% | Q1 2016 | Q1 2016 | 1 |
VTGN | VISTAGEN THERAPEUTICS INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q2 2016 | Q2 2016 | 1 |
XFOR | X4 PHARMACEUTICALS INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q1 2021 | Q1 2021 | 1 |
CLBS | CALADRIUS BIOSCIENCES INC | 1 | 1 | 0.14% | 0.14% | 0.14% | Q2 2015 | Q2 2015 | 1 |
CASC | CASCADIAN THERAPEUTICS... | 1 | 1 | 0.13% | 0.13% | 0.13% | Q2 2016 | Q2 2016 | 1 |
DRAD | DIGIRAD CORP | 1 | 1 | 0.13% | 0.13% | 0.13% | Q2 2013 | Q2 2013 | 1 |
PRTO | PROTEON THERAPEUTICS INC | 1 | 1 | 0.10% | 0.10% | 0.10% | Q4 2014 | Q4 2014 | 1 |
PRVB | PROVENTION BIO INC | 1 | 1 | 0.10% | 0.10% | 0.10% | Q2 2020 | Q2 2020 | 1 |
TNXP | TONIX PHARMACEUTICALS ... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q1 2017 | Q1 2017 | 1 |
INTEC PHARMA LTD JERUS... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q3 2017 | Q3 2017 | 1 | |
NWBO | NORTHWEST BIOTHERAPEUT... | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2014 | Q2 2014 | 1 |
FTSV | FORTY SEVEN INC | 1 | 1 | 0.08% | 0.08% | 0.08% | Q2 2018 | Q2 2018 | 1 |
TRILLIUM THERAPEUTICS INC | 1 | 1 | 0.06% | 0.06% | 0.06% | Q2 2017 | Q2 2017 | 1 | |
UMRX | UNUM THERAPEUTICS INC | 1 | 1 | 0.04% | 0.04% | 0.04% | Q1 2018 | Q1 2018 | 1 |
GNVC | GENVEC INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q4 2016 | Q4 2016 | 1 |
CLSD | CLEARSIDE BIOMEDICAL INC | 1 | 1 | 0.03% | 0.03% | 0.03% | Q1 2018 | Q1 2018 | 1 |
ACELYRIN INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2023 | Q3 2023 | 1 | |
CRDF | CARDIFF ONCOLOGY INC | 1 | 1 | 0.02% | 0.02% | 0.02% | Q3 2020 | Q3 2020 | 1 |
BVXV | BIONDVAX PHARMACEUTICA... | 1 | 1 | 0.01% | 0.01% | 0.01% | Q1 2018 | Q1 2018 | 1 |
ONTX | ONCONOVA THERAPEUTICS INC | 1 | 1 | 0.00% | 0.00% | 0.00% | Q2 2016 | Q2 2016 | 1 |
OPXA | OPEXA THERAPEUTICS INC | 1 | 1 | 0.00% | 0.00% | 0.00% | Q1 2015 | Q1 2015 | 1 |
Download |
The securities at the top of the list , including STEREOTAXIS INC, ATRICURE INC, and MASIMO CORPORATION, are the highest-conviction holdings of DAFNA Capital Management LLC.
The conviction is calculated by counting the number of quarters a security has been reported by DAFNA Capital Management LLC. The higher the number, the higher the conviction and longer the holding period.
This page lists all the securities that DAFNA Capital Management LLC owns currently or has owned in the past.